share_log

10-Q: Q2 2024 Earnings Report

10-Q: Q2 2024 Earnings Report

10-Q：2024财年二季报
美股SEC公告 ·  2024/07/31 15:11

Moomoo AI 已提取核心信息

Teva Pharmaceutical reported Q2 2024 revenues of $4.16 billion, up 7% year-over-year, driven by higher generic product sales across all segments and strong AUSTEDO growth. AUSTEDO revenues surged 32% to $407 million while generic product revenues in the US increased 16% to $1.02 billion. Gross profit margin improved to 48.6% from 46.3% last year.The company recorded a net loss of $846 million, impacted by a $400 million goodwill impairment charge related to its API business unit and $630 million in tax expenses following a settlement with Israeli tax authorities. Operating loss narrowed to $5 million from $654 million last year, as legal settlement expenses decreased significantly to $83 million from $462 million.Looking ahead, Teva continues executing its Pivot to Growth strategy focused on innovative medicines and biosimilars while sustaining its generics business. The company generated free cash flow of $324 million and maintained $2.26 billion in cash. Management expects to complete the planned divestiture of its API business in the first half of 2025 as part of its strategic transformation.
Teva Pharmaceutical reported Q2 2024 revenues of $4.16 billion, up 7% year-over-year, driven by higher generic product sales across all segments and strong AUSTEDO growth. AUSTEDO revenues surged 32% to $407 million while generic product revenues in the US increased 16% to $1.02 billion. Gross profit margin improved to 48.6% from 46.3% last year.The company recorded a net loss of $846 million, impacted by a $400 million goodwill impairment charge related to its API business unit and $630 million in tax expenses following a settlement with Israeli tax authorities. Operating loss narrowed to $5 million from $654 million last year, as legal settlement expenses decreased significantly to $83 million from $462 million.Looking ahead, Teva continues executing its Pivot to Growth strategy focused on innovative medicines and biosimilars while sustaining its generics business. The company generated free cash flow of $324 million and maintained $2.26 billion in cash. Management expects to complete the planned divestiture of its API business in the first half of 2025 as part of its strategic transformation.
Teva 药品公司公布2024年第二季度收入为41.6亿美金，同比增长7%，这是由于所有板块的仿制药销售增加以及AUSTEDO的强劲增长所驱动。AUSTEDO的收入猛增32%，达到40700万美金，而美国的仿制药收入也增长了16%，达到10.2亿美金。毛利润率从去年的46.3%提高到48.6%。公司记录了84600万美金的净亏损，这受到与其API业务部门相关的40000万美金商誉减值费用及与以色列税务机关达成和解后的63000万美金税费的影响。经营亏损从去年的65400万美金缩小至500万美金，法律和解费用显著减少，从46200万美金降至8300万美金。展望未来，Teva将继续执行其聚焦创新药物和生物类似药的增长策略，同时维持其仿制药业务。公司产生了32400万美金的自由现金流，并保持了22.6亿美金的现金。管理层预计将在2025年上半年完成其API业务的计划剥离，作为其战略转型的一部分。
Teva 药品公司公布2024年第二季度收入为41.6亿美金，同比增长7%，这是由于所有板块的仿制药销售增加以及AUSTEDO的强劲增长所驱动。AUSTEDO的收入猛增32%，达到40700万美金，而美国的仿制药收入也增长了16%，达到10.2亿美金。毛利润率从去年的46.3%提高到48.6%。公司记录了84600万美金的净亏损，这受到与其API业务部门相关的40000万美金商誉减值费用及与以色列税务机关达成和解后的63000万美金税费的影响。经营亏损从去年的65400万美金缩小至500万美金，法律和解费用显著减少，从46200万美金降至8300万美金。展望未来，Teva将继续执行其聚焦创新药物和生物类似药的增长策略，同时维持其仿制药业务。公司产生了32400万美金的自由现金流，并保持了22.6亿美金的现金。管理层预计将在2025年上半年完成其API业务的计划剥离，作为其战略转型的一部分。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Petros Pharmaceuticals
    PTPI
    -- 0.2930
    坎伯兰药业
    CPIX
    -- 5.150
    OptiNose
    OPTN
    -- 6.000
    Talphera
    TLPH
    -- 0.670
    BioAge Labs
    BIOA
    -- 4.790
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    多家机构看多！中国资产将全面重估：你会如何布局？
    近期，Goldman Sachs、Morgan Stanley、Appaloosa LP等多家机构唱好中国资产。 🎙️讨论： 1. Deepseek引爆中国资产上涨，后市你怎么看？ 2. 多家中国企业1月表现提升，你更看好谁？ 展开
    中国的资产重估引发了讨论：mooer们在买什么？